ALVO vs. MRNA, VTRS, RDY, ASND, SRPT, PCVX, QGEN, ROIV, RVMD, and LNTH
Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.
Alvotech vs.
Alvotech (NASDAQ:ALVO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
In the previous week, Moderna had 10 more articles in the media than Alvotech. MarketBeat recorded 21 mentions for Moderna and 11 mentions for Alvotech. Alvotech's average media sentiment score of 0.58 beat Moderna's score of 0.35 indicating that Alvotech is being referred to more favorably in the media.
Alvotech presently has a consensus price target of $18.00, indicating a potential upside of 54.37%. Moderna has a consensus price target of $59.00, indicating a potential upside of 74.30%. Given Moderna's higher probable upside, analysts plainly believe Moderna is more favorable than Alvotech.
Moderna has a net margin of -110.04% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Moderna's return on equity.
Moderna received 208 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 53.88% of users gave Moderna an outperform vote while only 50.00% of users gave Alvotech an outperform vote.
75.3% of Moderna shares are held by institutional investors. 0.5% of Alvotech shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Alvotech has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.
Alvotech has higher earnings, but lower revenue than Moderna. Alvotech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Summary
Moderna beats Alvotech on 13 of the 19 factors compared between the two stocks.
Get Alvotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alvotech Competitors List
Related Companies and Tools
This page (NASDAQ:ALVO) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy ALVO Stock Free ALVO Stock Alerts